Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Twitter may be worth only a third of its pre-Musk value, Fidelity says
Kenya panel urges shutdown of Worldcoin's crypto project within country
Hubble Space Telescope goes down for third time in a week
The Best Fuji X Lenses for 2023
Autel Energy to Showcase Innovative EV Charging Solutions at Power2Drive Europe 2023
Meta’s ‘Year of Efficiency’ Is Coming to an End. Analysts Aren’t Worried.
China-based hackers breached Western European government email accounts, Microsoft says
Trump news - live: Trump calls special prosecutor a ‘crackhead’ in response to White House cocaine discovery